A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 299 participants.

Also called NCT01678820

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 299 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01678820
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01678820. Randomized; double masking; primary purpose treatment. Start 2012-10-10 (actual); primary completion 2013-11-01 (actual). Results posted on 2014-10-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin/Simvastatin FDC
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Simvastatin
Intervention (Drug)
Placebo to sitagliptin
Intervention (Drug)
Placebo to simvastatin
Intervention (Drug)
Placebo to Sitagliptin/Simvastatin FDC
Intervention (Drug)
Metformin
Intervention (Drug)
Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01678820
Content hash
6c4c16b76107442b4a58f8d4dc5be122f1d2daf400efcd3c4eb8c7968de070df